Compare Amgen, Inc. (AMGN) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Franklin Resources, Inc. — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Franklin Resources, Inc. trades at $33.64 (market cap $17.41B). The key difference: Amgen, Inc. is far larger — about 11.3× Franklin Resources, Inc.'s market cap, and Franklin Resources, Inc. pays the higher dividend (3.94%). Which is the better fit depends on your goals.
| AMGN | BEN | |
|---|---|---|
Market Cap | $196.12B | $17.41B |
Sector | Health | Financials |
52-Week High | $388.16 | $34.44 |
52-Week Low | $271.18 | $21.18 |
Enterprise Value | $241.41B | $29.23B |
Dividend Yield | 2.77% | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Franklin Resources (BEN) trades at $33.50, down 0.53% on the day, with a bullish technical outlook from moving averages and a consensus price target of $34.17. The company reported Q1 2026 EPS of $0.71, beating expectations of $0.55, and maintains strong profitability with an 80.72% gross margin. Recent news highlights its inclusion in dividend stock lists and a Zacks upgrade to Strong Buy on June 23, 2026, amid steady asset growth to $1.79 trillion AUM in June.
BEN presents a mixed outlook with solid earnings beats and dividend appeal offset by weak cash flow trends and modest growth. Upside is supported by analyst optimism and technical momentum, but risks include net cash outflows and competitive pressures in asset management. The stock's valuation at a P/E of 25.57 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
